Advertisement
Canada markets closed
  • S&P/TSX

    21,642.87
    -97.33 (-0.45%)
     
  • S&P 500

    5,051.41
    -10.41 (-0.21%)
     
  • DOW

    37,798.97
    +63.86 (+0.17%)
     
  • CAD/USD

    0.7234
    -0.0019 (-0.27%)
     
  • CRUDE OIL

    85.31
    -0.10 (-0.12%)
     
  • Bitcoin CAD

    88,006.17
    +630.39 (+0.72%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,399.50
    +16.50 (+0.69%)
     
  • RUSSELL 2000

    1,967.48
    -8.23 (-0.42%)
     
  • 10-Yr Bond

    4.6590
    +0.0310 (+0.67%)
     
  • NASDAQ futures

    17,894.00
    +17.75 (+0.10%)
     
  • VOLATILITY

    18.40
    -0.83 (-4.32%)
     
  • FTSE

    7,820.36
    -145.17 (-1.82%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • CAD/EUR

    0.6808
    -0.0016 (-0.23%)
     

Is Myovant Sciences' (NYSE:MYOV) 152% Share Price Increase Well Justified?

Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares in, you can make more than you can lose. For example, the Myovant Sciences Ltd. (NYSE:MYOV) share price has soared 152% in the last year. Most would be very happy with that, especially in just one year! It's also good to see the share price up 52% over the last quarter. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report. Looking back further, the stock price is 35% higher than it was three years ago.

See our latest analysis for Myovant Sciences

Myovant Sciences wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

ADVERTISEMENT

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Myovant Sciences stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

It's nice to see that Myovant Sciences shareholders have gained 152% (in total) over the last year. So this year's TSR was actually better than the three-year TSR (annualized) of 10%. The improving returns to shareholders suggests the stock is becoming more popular with time. It's always interesting to track share price performance over the longer term. But to understand Myovant Sciences better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with Myovant Sciences (including 1 which is is concerning) .

If you are like me, then you will not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.